ArticleJournal of human reproductive sciences
Individualisation of the Dose of Letrozole for Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome Based on Clinical and Ultrasonography Criteria: A Cohort Study.
Article in Journal of human reproductive sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conventionally, letrozole for ovulation induction (OI) in polycystic ovary syndrome (PCOS) is started at a dose of 2.5 mg, which is gradually escalated depending on the follicular response. The minimum dose required for follicular response for a particular patient is yet to be determined. Aim: The aim of the study was to compare various clinical and ultrasonographic characteristics of patients with successful OI with different doses of letrozole and individualise the dose of letrozole. Setting and Design: This prospective cohort study was conducted in a tertiary care teaching hospital from December 2019 to March 2024. Materials and Methods: Ninety-seven patients were treated with a starting dose of 2.5 mg of letrozole. The dose was increased to 5 and 7.5 mg without a follicular response. Various clinical and ultrasonographic characteristics were compared. Statistical Analysis Used: Data entered in Microsoft Excel and analysed using SPSS version 27. Results: Of 97 patients, 10 were lost to follow-up. Eighty-one (93.1%) patients had a positive response to letrozole. Six (6.9%) patients did not respond to the maximum dose of 7.5 mg of letrozole. Waist circumference, maximum antral follicle count per ovary and volume of the largest ovary were significantly different for patients who responded to different doses of letrozole ( Conclusion: The ovarian volume can be considered when determining the dose of letrozole in PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.